Product Pathways - Protein Stability
SignalSilence® ADRM1 siRNA I #7981
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Western blot analysis of extracts from 293T cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® ADRM1 siRNA I (+), or SignalSilence® ADRM1 siRNA II #8536 (+), using ADRM1 Antibody #8549 (upper) or GAPDH (D16H11) XP® Rabbit mAb #5174 (lower). The ADRM1 Antibody confirms silencing of ADRM1 expression, while the GAPDH (D16H11) XP® Rabbit mAb is used as a loading control.
SignalSilence® ADRM1 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit ADRM1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
CST recommends transfection with 100 nM SignalSilence® ADRM1 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
Currently, there are five ubiquitin receptors associated with the proteasome: two proteasome subunits, Rpn10/S5a/PSMD4 and Rpn13/ADRM1 (Adhesion-regulating molecule 1), and three families of shuttling factors, Rad23, Dsk2, and Ddi1. ADRM1 is a ubiquitin receptor of the proteasome (1,2) that binds ubiquitin via a pleckstrin homology domain known as the pleckstrin-like receptor for ubiquitin (Pru) domain. The carboxy-terminal domain of mammalian ADRM1 serves to bind and enhance the isopeptidase activity of UCHL5/UCH37 (3-5), perhaps serving as a mechanism to accelerate ubiquitin chain disassembly. A murine Adrm1 knockout results in defective gametogenesis, thus highlighting a physiologic role for endogenous ADRM1 in mammalian development (6).
- Schreiner, P. et al. (2008) Nature 453, 548-52.
- Husnjak, K. et al. (2008) Nature 453, 481-8.
- Yao, T. et al. (2006) Nat Cell Biol 8, 994-1002.
- Hamazaki, J. et al. (2006) EMBO J 25, 4524-36.
- Qiu, X.B. et al. (2006) EMBO J 25, 5742-53.
- Al-Shami, A. et al. (2010) PLoS One 5, e13654.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 6568 SignalSilence® Control siRNA (Unconjugated)
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 8536 SignalSilence® ADRM1 siRNA II
- 8549 ADRM1 Antibody
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
For Research Use Only. Not For Use In Diagnostic Procedures.